Abstract:2 ГБОУ «Клинический онкологический диспансер № 1» министерства здравоохранения Краснодарского края. Россия, 350040, г. Краснодар, ул. Димитрова, 146 В обзоре приведена констелляция существующих фактов и аргументов о паратиреоидном гормон-род ственном белке и его участии в патофизиологических и патобиохимических механизмах, связанных с онкотрансформацией ткани предстательной железы. Паратиреоидный гормон-родственный белок является мультипотентной молекулой, из которой в результате протеолитического процессинг… Show more
A rare scintigraphic phenomenon of “superscan” is considered – an abnormally high diffuse accumulation of osteotropic radiopharmaceutical by all skeletal parts in combination with the absence of kidney and tissue background imaging. This feature reflects a generalized bone system lesion of metastatic, metabolic or hematological nature. We present a clinical observation and retrospective assessment of scintigraphic data obtained during controlling androgen deprivation therapy in a patient with prostate cancer. Based on the analysis of “superscan” signs, including 99mТс-pyrophosphate hyperfixation by skull bones, as well as concomitant levels of prostatic specific antigen and parathyroid hormone (PTH), it was suggested that the identified scintigraphic phenomenon had metabolic nature, and its occurrence was possibly due to ectopic production of both PTH and parathyroid hormone-related protein, playing a well-known role in prostate cancer genesis.
A rare scintigraphic phenomenon of “superscan” is considered – an abnormally high diffuse accumulation of osteotropic radiopharmaceutical by all skeletal parts in combination with the absence of kidney and tissue background imaging. This feature reflects a generalized bone system lesion of metastatic, metabolic or hematological nature. We present a clinical observation and retrospective assessment of scintigraphic data obtained during controlling androgen deprivation therapy in a patient with prostate cancer. Based on the analysis of “superscan” signs, including 99mТс-pyrophosphate hyperfixation by skull bones, as well as concomitant levels of prostatic specific antigen and parathyroid hormone (PTH), it was suggested that the identified scintigraphic phenomenon had metabolic nature, and its occurrence was possibly due to ectopic production of both PTH and parathyroid hormone-related protein, playing a well-known role in prostate cancer genesis.
Background. The present article studies a possible role of parathyroid hormone-related protein (PTHrP) in urolithiasis pathogenesis.Aim. To consider PTHrP level as a predictor of the urolithiasis development.Material and methods. We presented an analysis of treatment in 79 patients with primary and recurrent nephrolithiasis that had underwent surgical treatment in the Uronephrological Center of Scientific Research Institute – Ochapovsky Regional Clinical Hospital #1, Krasnodar from 2017 to 2019. All observed patients were divided in two groups: patients with primary and recurrent nephrolithiasis. A group of 10 relatively healthy people was included in the study as well. All patients and conditionally healthy people had a test for blood parameters; in particular, the level of parathyroid hormone-related protein was assessed in order to compare the indicators in all three groups.Conclusions. The PTHrP level was showed to be statistically significantly different in patients with urolithiasis from the group with relatively healthy people. Groups with primary and recurrent nephrolithiasis show not difference in the level of PTHrP. Further studies are necessary to consider this protein as one of the predictors of urolithiasis and study its role in the pathogenesis of nephrolithiasis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.